3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.
Head and neck squamous cell carcinoma (HNSCC) is significantly underrepresented in worldwide cancer research, yet survival rates for the disease have remained static for over 50 years. Distant metastasis is often present at the time of diagnosis, and is the primary cause of death in cancer patients. In the absence of routine effective targeted therapies, the standard of care treatment remains chemoradiation in combination with (often disfiguring) surgery. A defining characteristic of HNSCC is the amplification of a region of chromosome 3 (3q26-29), which is consistently associated with poorer patient outcome. This review provides an overview of the role the 3q26-29 region plays in HNSCC, in terms of both known and as yet undiscovered processes, which may have potential clinical relevance.
Cancer Research UK Beatson Institute, Glasgow, UK.
Matthew A
MA
Davidson
Cancer Research UK Beatson Institute, Glasgow, UK.
Emma J
EJ
Shanks
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D005784:Gene Amplification; D056726:Genetic Association Studies; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D009857:Oncogenes

HNSCC
; 3q26-29; HPV-negative; PI3K/AKT; RNA-binding protein; insulin signalling